A randomized, open-label study of the effect of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus on preservation of renal function and prevention of acute rejection in recipients of an orthotropic liver transplant.

Trial Profile

A randomized, open-label study of the effect of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus on preservation of renal function and prevention of acute rejection in recipients of an orthotropic liver transplant.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2013

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Sirolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STN; STN
  • Sponsors Roche
  • Most Recent Events

    • 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
    • 18 Aug 2008 Status change from in progress to completed according to the Roche protocol registry.
    • 04 Jun 2008 Interim results presented at the American Transplant Congress (ATC) 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top